LUPIN

gets BUY from Citi amid Vitabiotics' acquisition talks

Lupin Shares Price Target: India’s drugmaker Lupin saw its share price dip nearly half a per cent on the BSE. The slight dip has prompted questions on whether this presents a buying opportunity. Investment banking firm Citi has analysed the company and provided a price target along with a stock recommendation. Citi on Lupin Brokerage firm Citi has maintained a BUY call on the Indian drugmaker. The company has set a target price of Rs 2,260, implying an upside of around 9 per cent from current levels.